Gameto vs Regeneron

Side-by-side comparison of AI visibility scores, market position, and capabilities

Regeneron leads in AI visibility (75 vs 41)
Gameto logo

Gameto

EmergingBioTech

Reproductive Medicine

Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimulation duration from 10 days to 2–3 days, making fertility treatment faster, cheaper, and less invasive.

AI VisibilityBeta
Overall Score
C41
Category Rank
#1 of 1
AI Consensus
53%
Trend
up
Per Platform
ChatGPT
49
Perplexity
39
Gemini
32

About

Gameto is revolutionizing in vitro fertilization by engineering ovarian granulosa cells from stem cells that can mature patient eggs in the lab, eliminating the lengthy and hormone-intensive stimulation protocols required by conventional IVF. The company's Fertilo technology co-incubates patient egg cells with Gameto's lab-grown granulosa cells, achieving maturation in 2–3 days versus the 10+ days of hormone injections that characterize standard IVF stimulation.

Full profile
Regeneron logo

Regeneron

LeaderLife Sciences & BioTech

Biopharmaceuticals

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.

AI VisibilityBeta
Overall Score
B75
Category Rank
#2 of 2
AI Consensus
73%
Trend
up
Per Platform
ChatGPT
72
Perplexity
76
Gemini
84

About

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.

Full profile

AI Visibility Head-to-Head

41
Overall Score
75
#1
Category Rank
#2
53
AI Consensus
73
up
Trend
up
49
ChatGPT
72
39
Perplexity
76
32
Gemini
84
51
Claude
77
40
Grok
79

Key Details

Category
Reproductive Medicine
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Gameto
Reproductive Medicine
Only Regeneron
Biopharmaceuticals

Integrations

Only Regeneron

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.